Navigation Links
Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms
Date:7/27/2009

COLLEGEVILLE, Pa., July 27 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced the publication in Fertility and Sterility of data from a Phase 3 clinical study that showed that the investigational compound bazedoxifene/conjugated estrogens (BZA/CE) significantly reduced the frequency and severity of hot flushes and improved measures of vaginal atrophy when compared to placebo. In this study, uterine bleeding was not statistically different from placebo and the rate of endometrial hyperplasia in doses being considered for therapeutic use was <1%. BZA/CE is being studied by Wyeth Pharmaceuticals for the treatment of moderate-to-severe menopausal vasomotor symptoms such as hot flushes, night sweats and vulvar and vaginal atrophy, and for the prevention of postmenopausal osteoporosis.

The data, published online July 27, 2009 in the peer-reviewed journal Fertility and Sterility, is from the Selective estrogens Menopause And Response to Therapy (SMART-1) clinical trial. SMART-1 was designed to explore the hypothesis that bazedoxifene, when paired with conjugated estrogens, may have the potential to eliminate the need for progestin in menopausal therapy in women with an intact uterus. BZA/CE is characterized by Wyeth as a TSEC (tissue selective estrogen complex) as it combines a selective estrogen receptor modulator (SERM) with conjugated estrogens.

Across the SMART-1 trial, the incidence of treatment-emergent adverse events, breast pain, serious adverse events and withdrawals due to adverse events were similar among the active treatment groups and placebo.

About SMART-1

SMART-1 was a two-year, multinational, multicenter, randomized, double-blind, placebo- and active-control
'/>"/>

SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
3. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
4. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
5. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
6. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
7. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
8. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
9. Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
10. Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
11. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Top-Line Data Expected in the Third Quarter --, ... VIAP ), a biotechnology company focused on the development ... that,it has completed the last patient visit in its ... be analyzed to determine,VIA-2291,s effect on inflammation, and the ...
... Modigene,s CTP Technology for Extending ... of Action of Therapeutic Proteins -, NES-ZIONA, Israel, ... noted the successful completion of a Phase,III clinical trial ... uses the naturally occurring CTP,peptide to extend the duration ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Modigene Platform Validated in Independent Phase III Trial of CTP Technology 2Modigene Platform Validated in Independent Phase III Trial of CTP Technology 3
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... Calif., June 24 Novasys Medical, Inc., a developer ... as of July 1, 2009, First Coast Service Options, ... over 3 million beneficiaries in Florida, Puerto Rico and ... treatment for women with stress urinary incontinence (SUI) from ...
... Plans (MHP) is pleased to offer Mercy One ... www.mercyhealthplans.com . This online quoting and sales ... and brokers with Mercy One (TM), health insurance for ... Connect(TM) utilizes a customer-friendly online ecommerce platform that ...
... Purchase Agreement will expedite the purchasing process for groups ... IRVINE, Calif., June 24 ChromaDex Corp., (OTC Bulletin ... contract research, announced today that the National Institutes of ... Company. The Agreement covers all products and services ...
... , , , , Chocolate and ... June 24 Experimenting with flavors, flexibility and variety, ... with chocolate and candy innovation that will drive consumer purchasing ... Association,s (NCA) Confectionery Industry Trend Report 2009. Even in economic ...
... CNI ... Technician Executive Division of the California Society of Health System Pharmacists. , ... Orange, CA (PRWEB) June 24, 2009 -- CNI ... for the Technician Executive Division of the California Society of Health System Pharmacists. As ...
... Vet-A-Mix announces ... at-risk horses. , ... (PRWEB) June 24, 2009 -- Equine obesity is on the rise in the United States. ... higher risk for laminitis: a debilitating condition responsible for thousands of deaths each year. According ...
Cached Medicine News:Health News:First Coast Medicare to Provide Case by Case Reimbursement for the Renessa(R) Treatment for Incontinence in Women 2Health News:First Coast Medicare to Provide Case by Case Reimbursement for the Renessa(R) Treatment for Incontinence in Women 3Health News:Mercy Health Plans Launches MercyOne Connect(TM) 2Health News:ChromaDex Establishes a Blanket Purchase Agreement With the National Institutes of Health 2Health News:Confectionery Industry Forecast Is Sweet: Globally Inspired Flavors, Eco-Friendly and Health Minded Trends Lead New Product Innovations 2Health News:Confectionery Industry Forecast Is Sweet: Globally Inspired Flavors, Eco-Friendly and Health Minded Trends Lead New Product Innovations 3Health News:Confectionery Industry Forecast Is Sweet: Globally Inspired Flavors, Eco-Friendly and Health Minded Trends Lead New Product Innovations 4Health News:Confectionery Industry Forecast Is Sweet: Globally Inspired Flavors, Eco-Friendly and Health Minded Trends Lead New Product Innovations 5Health News:Confectionery Industry Forecast Is Sweet: Globally Inspired Flavors, Eco-Friendly and Health Minded Trends Lead New Product Innovations 6Health News:CNI Pharmacy Technician Program 2Health News:Equine Obesity is Associated with Significant Health Issues, Including Insulin Resistance and Laminitis 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
This unit is the finest standalone handswitch bipolar unit available....
...
...
Medicine Products: